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Abstract
Purpose Most guidelines about fertility preservation are predominantly focused on scientific evidence, but are less practically 
orientated. Therefore, practically oriented recommendations are needed to support the clinician in daily practice.
Methods A selective literature search was performed based on the clinical and scientific experience of the authors, focussing 
on the most relevant diseases and gynaecological cancers. This article (Part I) provides information on topics that are essential 
for the fertility preservation indication, such as disease prognosis, disease therapy and its associated risks to fertility, recom-
mending disease-specific fertility preservation measures. Part II specifically focusses on fertility preservation techniques.
Results In breast cancer patients, fertility preservation such as ovarian tissue and oocyte cryopreservation is especially rec-
ommended in low-stage cancer and in women < 35 years of age. In Hodgkin’s lymphoma, the indication is mainly based on 
the chemotherapy regime as some therapies have very low, others very high gonadotoxicity. In borderline ovarian tumours, 
preservation of fertility usually is achieved through fertility sparing surgery, ovarian stimulation may also be considered. In 
cervical cancer, endometrial cancer, rheumatic diseases and other malignancies such as Ewing sarcoma, colorectal carcinoma, 
non-Hodgkin lymphoma, leukaemia etc., several other factors must be considered to enable an individual, stage-dependent 
decision.
Conclusion The decision for or against fertility preservation depends on the prognosis, the risks to fertility and individual 
factors such as prospective family planning.
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Introduction
Fertility preservation techniques have become an estab-
lished part of oncology, rheumatology and many other 
areas. Several guidelines and recommendations have 
been published in Europe [1], the United States [2] and 
elsewhere. These guidelines mainly focus on scientific 
evidence, but are less practically orientated. The Ferti-
PROTEKT network, a network and society of physicians 
and biologists specializing in fertility preservation in Ger-
many, Austria and parts of Switzerland already published 
practical recommendations [3]. These recommendations 
have been updated, focusing on indications for fertility 
preservation, as well as on fertility preservation tech-
niques in women who require therapies which can poten-
tially lead to ovarian failure. As the topic has become too 
broad for one single paper, we have prepared two arti-
cles. This first article (Part I) provides disease-associated 
information, which is required for recommending fertility 
preservation procedures; a second article (Part II), also 
published in this journal, provides information about fer-
tility preservation techniques. We aim to focus on top-
ics that are essential in deciding for or against fertility 
preservation such as disease prognosis, disease-specific 
therapy and associated risks to fertility and to recommend 
disease-specific fertility preservation measures (Fig. 1).
Breast cancer
Prognosis
The prognosis of breast cancer is influenced by the tumour 
stage, intrinsic subtype and genetic classification. Stages 
II, III and IV display a mortality rate of 20, 44 and 66%, 
respectively in women with breast cancer < 40 years [4]. 
Triple negative breast cancer or a luminal B-type tumour are 
associated with an adverse prognosis [5]. While the overall 
10-year survival rate in all women with breast cancer is 86%, 
the prognosis of younger patients < 35 years is significantly 
lower, as aggressive subtypes and negative prognostic fac-
tors are more frequent in young women [6]. In young women 
with breast cancer diagnosed at age < 35 years, it has been 
shown that the survival rate decreases by 5% for each year 
of lower age at diagnosis [7].
Risks to fertility
The chemotherapy-related risk of premature ovarian insuffi-
ciency (POI) is influenced by age, body mass index, the type 
and duration of therapy. After six cycles of CMF, the risk of 
amenorrhoea is 33 and 81% in patients < 40 and ≥ 40 years 
of age, respectively [8]. Lower rates of persisting amen-
orrhoea were observed for newer therapy regimes such 
as AC-, ACT-, FAC- and FACT. In women < 30 years, 
the risk of amenorrhoea was 10–20%, but 13–68% for 
women > 30 years [9] (Table 1).
Fig. 1  Decision tree for fertility 
preservation: criteria to decide 
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tion in women
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While adjuvant endocrine therapies are not gonadotoxic 
per se, the long duration of therapy poses a significant 
risk to fertility because of the natural decline in the ovar-
ian reserve during therapy. Therefore, the increased age at 
the time when endocrine therapy is completed needs to be 
considered, if fertility preservation measures are discussed 
[10]. However, endocrine therapy may be interrupted for 
pregnancy after 2–3 years and can be continued afterwards, 
if patients are willing to accept a possibly increased risk for 
recurrence [11].
Risk of ovarian metastasis
The risk of ovarian metastasis is increased in higher 
tumour stages with peripheral metastases, in inflammatory 
and in lobular breast cancer. In tumours with negative 
lymph nodes, the risk of ovarian metastasis is low. Even 
in younger patients in higher disease stages and positive 
lymph nodes, the risk of ovarian metastasis at diagnosis 
seems to be low, but limited data are available [12–14]. 
In a study with 2648 young women with breast cancer 
of whom 2.4% had the diagnosis of ovarian metastasis, 
the median latency up to diagnosis of ovarian metastasis 
was 49 months [15]. In a small series using ovarian tissue 
from 13 women with advanced breast cancer, no metas-
tases were observed after xenotransplantation into SCID 
mice [16].
The risk for women with BRCA1- and BRCA2-posi-
tive breast cancer of developing primary ovarian cancer is 
15–65% [17]. In BRCA1- and BRCA2-positive women with 
Table 1  Risk to fertility 
by gonadotoxic agents and 
regimes. Modified from [1, 113, 
114]
HSC-TX hematopoietic stem cell transplantation, TBI total body irradiation, CMF cyclophosphamide, 
methotrexate, fluorouracil, CEF cyclophosphamide, epirubicin, fluorouracil, CAF cyclophosphamide, dox-
orubicin, fluorouracil, TAC docetaxel, doxorubicin, cyclophosphamide, BEACOPP doxorubicin, bleomy-
cin, vincristine, etoposide, cyclophosphamide, procarbazine, AC doxorubicin, cyclophosphamide, EC epi-
rubicin, cyclophosphamide, MTX methotrexate, ABVD doxorubicin, bleomycin, vinblastine, dacarbazine, 
CHOP cyclophosphamide, doxorubicin, vincristine, prednisone, CVP cyclophosphamide, vincristine, pred-
nisone, AML acute myeloid leukaemia, ALL acute lymphatic leukaemia
Risk category Risk of permanent amen-
orrhoea
Agent/regime
High risk 80% HSC-TX with cyclophosphamide/TBI or cyclo-
phosphamide/busulfan
External beam radiotherapy including the ovaries
BEACOPP escalated (≥ 30 years)
6× CMF, CEF, CAF, TAC (≥ 40 years)
Procarbazine
Chlorambucil
Intermediate risk 40–60% BEACOPP escalated (< 30 years)
6× CMF, CEF, CAF, TAC (30–39 years)
4× AC (≥ 40 years)
4× AC or EC → Taxanes
30% Monoclonal antibody: bevacizumab
12–54% MTX (cumulative risk increased in repeated 
treatment of autoimmune disorders)
Low risk < 20% ABVD (≥ 32 years)
4–6× CHOP
CVP
AML therapy (anthracycline/cytarabine)
ALL therapy (multi-agent)
6× CMF, CEF, CAF, TAC (≤ 30 years)
4× AC (≤ 40 years)
Very low or no risk – ABVD (< 32 years)
Methotrexate
Fluorouracil
Vincristine
Tamoxifen
Unknown risk – Monoclonal antibodies: trastuzumab, cetuximab
Tyrosine kinase inhibitors: erlotinib, imatinib
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prophylactic salpingo-oophorectomy, the ovaries showed 
occult primary ovarian cancer in 6 and 2%, respectively [18].
Fertility preservation measures
GnRH agonists have previously been suspected to impair the 
benefit of chemotherapy in hormone-sensitive breast cancer 
by causing ovarian suppression. However, as recent studies 
starting the endocrine ovarian suppression simultaneously 
with the (neo) adjuvant chemotherapy have questioned such 
a negative effect [19], this treatment option can be consid-
ered even in hormone-sensitive breast cancer.
Ovarian stimulation with oocyte cryopreservation is pos-
sible and appears to be safe [20]. If this is discussed with 
a patient shortly after diagnosis, the time interval before 
adjuvant chemotherapy is usually sufficient to allow single 
or double ovarian stimulation [21].
In hormone-sensitive breast cancer, controlled ovar-
ian stimulation should be discussed individually with the 
patient and the oncologist. If stimulation is performed, 
estradiol levels should be reduced by aromatase inhibitors 
(or tamoxifene) and by GnRH agonist triggered ovulation 
without impairing clinical pregnancy rates and live birth 
rates in cryopreservation cycles [20, 22–24] and oncological 
follow-ups [25].
Ovarian tissue cryopreservation appears to be safe, espe-
cially in low tumour stages. The stage-dependent risk for 
ovarian metastases should be discussed with the patient. 
Ovarian cryopreservation should not be performed in stage 
IV breast cancer. In patients with BRCA1- and BRCA2-
positive breast cancer, ovarian cryopreservation appears to 
be possible. After completion of family planning, transplants 
should be removed.
Summarized recommendations
• Fertility preservation is recommended in women with 
breast cancer with a good prognosis, with a moderate 
to high POI risk and/or age > 35 years at the time of 
expected pregnancy.
• In hormone-insensitive breast cancer, GnRH agonists, 
ovarian stimulation for oocyte cryopreservation and ovar-
ian tissue cryopreservation can be offered.
• In hormone-sensitive tumours, GnRH agonists and ovar-
ian stimulation for oocyte cryopreservation should be 
discussed individually.
• If the time interval before chemotherapy is < 2 weeks, 
e.g., in a neo-adjuvant situation, stimulation is not an 
option and ovarian tissue cryopreservation should be 
considered.
• A combination of fertility preserving measures, and 
freezing the ovarian tissue followed by ovarian stimula-
tion with or without GnRH agonists can be offered.
Hodgkin’s lymphoma
Prognosis
Prognosis in Hodgkin’s lymphoma (HL) is age-related 
with high 15-year survival rates of 94, 91 and 87% in age 
groups of 18–29, 30–39 and 40–49 years, respectively [26, 
27]. Prognosis also depends on disease stage, risk factors 
and therapeutic response.
Risks to fertility
Early stages are treated with ABVD chemotherapy, for 
intermediate stages, the German Hodgkin Study Group 
recommends 2×BEACOPP escalated plus 2×ABVD and 
for advanced stages, 4–6×BEACOPP escalated. In other 
countries, ABVD remains the standard also for advanced 
HL. BEACOPP escalated is associated with significantly 
higher gonadotoxicity than ABVD [28] and this effect is 
age-dependent. After 8×BEACOPP escalated, the rate of 
amenorrhoea was 51.4% in women aged < 30 years and 
95.0% ≥ 30 years [29]. Comparing the gonadotoxic effects 
of ABVD and BEACOPP escalated, post-treatment serum 
AMH was 2.2 vs. 0.1 µg/l at age 18–29 years and 0.7 vs. 
0.0 µg/l at age 30–45 years [26]. While 90% of patients 
with early stages of HL who received ABVD ± 2×BEA-
COPP reported regular menstruation within 1  year of 
chemotherapy, amenorrhoea persisted in 25% of the 
25 years old and in 50% of the 30 years old patients 4 years 
after 6–8×BEACOPP escalated [26] (Table 1). Radiother-
apy in HL exerts an additional negative effect on fertility, 
when the ovaries are involved [30] (Table 2).
Table 2  Radiotoxicity and ovarian insufficiency. Modified from [96, 
112]
The ESD is defined as the radiotherapy dose, which reduces the ovar-
ian follicle pool to less than 1000 follicles in 97.5% of women [112]
Gy gray, ESD effective sterilizing dose
Ovarian effects of radiotherapy Ovarian radio-
therapy dose 
(Gy)
No relevant effects ≤0.6
No relevant effects < 40 years ≤1.5
Depletion of follicle pool by 50% 2.0
Risk of ovarian insufficiency 60% (15–40 years) 2.5–5.0
ESD 0 years (at birth) 20.3
ESD 10 years 18.4
ESD 20 years 16.5
ESD 30 years 14.3
ESD 40 years 6.0
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Risk of ovarian metastasis
Ovarian metastases were not detected in the four studies, 
including patients with advanced HL [14, 31, 32]. How-
ever, a case report observed HL within ovarian tissue in one 
patient in stage IIIb with hepatic involvement and pelvic 
lymphoma [33]. It can be concluded that the overall risk of 
ovarian metastasis is very low.
Fertility preservation measures
GnRH agonists and ovarian tissue cryopreservation are 
options for fertility preservation. Ovarian stimulation and 
oocyte cryopreservation is feasible, if the time interval 
before chemotherapy is sufficient to allow for stimulation. 
HL affecting the mediastinum can occasionally pose a risk 
for complications during intubation, making laparoscopy for 
ovarian cryopreservation impossible. Alternatively, if time is 
sufficient, ovarian stimulation can be offered, as transvaginal 
oocyte aspiration does not require intubation.
Summarized recommendations
• Fer t i l i ty  preser va t ion  i s  recommended in 
women < 40 years with high POI risk (e.g., 6×BEA-
COPP escalated).
• In women with a low or moderate POI risk (e.g., 
2×ABVD or 2×ABVD plus 2×BEACOPP escalated) 
fertility preservation can be considered.
• GnRH agonists, ovarian stimulation with oocyte cryo-
preservation and ovarian cryopreservation are adequate 
options for fertility preservation in HL.
• Laparoscopy for ovarian cryopreservation may not be 
possible in HL, if a mediastinal tumour impairs intuba-
tion.
• A combination of fertility preserving measures, GnRH 
agonists, and freezing of ovarian tissue followed by ovar-
ian stimulation may be an option, if gonadotoxic risk is 
high, prognosis is good and time is sufficient.
Borderline ovarian tumour and epithelial 
ovarian cancer
Prognosis
Borderline ovarian tumours (BOT) are mainly diagnosed at 
an early stage with favorable prognosis, characterized by the 
absence of invasive peritoneal implants [34]. The 10 year 
survival rate is 97% for all FIGO stages, for Stage III and 
IV it is 90% [35].
Epithelial ovarian carcinomas are often detected at 
advanced stages with a 5-year survival rate of 42%. In FIGO 
I, the 5-year survival rate is > 90%. The main prognostic 
factors are post-operative tumour mass and stage of disease, 
while others are age, constitution, grading, histologic type 
and guideline adherence during therapy.
Risks to fertility
Fertility in ovarian tumours is mainly compromised by the 
surgical procedure, but fertility sparing strategies exist. In 
epithelial ovarian cancer, chemotherapy can pose additional 
risks for fertility.
In BOT, guidelines require complete tumour removal, 
bilateral salpingo-oophorectomy and surgical staging, 
because the post-operative remaining tumour is the main 
prognostic factor. Chemotherapy is not indicated in BOT. 
In early epithelial ovarian carcinoma (FIGO IA, unilateral, 
G1), surgery involves complete tumour removal, bilateral 
salpingo-oophorectomy, hysterectomy, omentectomy, perito-
neal biopsies and pelvic and para-aortic lymphadenectomy. 
Chemotherapy is indicated in FIGO > IA, G1.
Fertility preservation measures
In unilateral BOT, the contralateral adnexa can be preserved. 
If both ovaries are involved, organ-preserving cystectomy is 
often feasible [36, 37]. After family planning is complete, 
surgery should be completed according to guidelines. Fer-
tility preserving surgery in BOT FIGO I is apparently not 
associated with a strong increase in oncological risk and 
fertility preservation is possible [38]. In retrospective obser-
vational studies, organ-preserving cystectomy resulted in an 
increased risk of recurrence [39]. In a large study, relapse 
rate after ovarian preservation was 12.5% in BOT FIGO I 
and 44% in BOT FIGO III, but only 13% in case of radical 
surgery [35]. Another study confirmed an increased relapse 
risk in the remaining ovarian tissue; however, no signifi-
cant effect on survival rates could be observed, even when a 
malignant transformation occurred [40].
In early epithelial ovarian cancer (FIGO IA, unilateral, 
G1), fertility sparing surgery to preserve the uterus and one 
healthy ovary is also feasible, after adequate staging and 
informed consent about associated risks. In well-selected 
patients, fertility preserving surgery is not associated with 
a change in the recurrence-free interval or survival rate 
[41–43]. Exact staging, risk assessment and oncological 
monitoring until birth are required. Completion of surgery 
is recommended, after family planning is complete.
Ovarian stimulation for oocyte cryopreservation can be 
considered in BOT, because of the risk of recurrence and 
especially before salpingo-oophorectomy is performed [38]. 
Although it is not known if ovarian stimulation increases the 
risk of BOT relapse, it has been recommended to restrict the 
number of cycles [44].
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In individual cases of early epithelial ovarian cancer 
(FIGO IA G1/G2) and after informed consent, in vitro fer-
tilization (IVF) may be an option. However, in a meta-anal-
ysis of small studies on IVF after fertility sparing surgery 
in ovarian carcinoma, a potentially negative effect on the 
oncological outcome was observed [45].
Ovarian tissue cryopreservation is not recommended in 
BOT and in epithelial ovarian carcinoma, because of the risk 
of ovarian metastasis. However, experimental methods such 
as in vitro growth of ovarian tissue (IVG) and xenotrans-
plantation of ovarian tissue into other species to generate 
follicles may become future strategies in malignant ovarian 
tumours.
Summarized recommendations
• In BOT and in early ovarian cancer FIGO IA G1 after 
complete staging, fertility sparing surgery to allow for 
pregnancy is feasible, followed by the completion of sur-
gery after delivery.
• In ovarian cancer FIGO IA G2 after complete staging, 
fertility sparing surgery and achievement of pregnancy 
can be considered in individual cases, followed by the 
completion of surgery and chemotherapy.
• Ovarian stimulation with oocyte cryopreservation can be 
offered to all patients with BOT, when ovarian reserve is 
compromised by surgery. Ovarian tissue cryopreserva-
tion is not recommended in ovarian carcinoma, because 
of the high risk of relapse, but can be considered in 
individual cases if bilateral salpingo-oophorectomy is 
required.
Cervical cancer
Prognosis
The prognosis of cervical cancer is stage-dependent, with a 
high 5-year survival rate of 93% for FIGO I. If lymph nodes 
are involved, the 5-year survival rate decreases to 20–60%, 
depending on the localization of metastases. Other important 
prognostic factors are lymphangiosis, haemangiosis, grad-
ing, histology and infiltration of resection margins.
Risks to fertility
Fertility in treatment of cervical cancer can be compromised 
by the surgical procedure and by radiochemotherapy. Organ-
preserving cone-biopsy or large loop excision of the trans-
formation zone (LLETZ) is performed for carcinoma in situ. 
While stages FIGO IA1, FIGO IA2 and selected cases of 
FIGO IB1 < 2 cm can also be treated with fertility sparing 
procedures, cervical carcinoma FIGO IB1 ≥ 2 cm requires 
radical hysterectomy with bilateral salpingectomy, which is 
not compatible with fertility. In cervical adenocarcinoma, 
bilateral oophorectomy is recommended due to a potential 
risk of ovarian metastasis; however, the ovaries can possibly 
be preserved in stage FIGO < IB2.
In the case of combined radiochemotherapy, the detri-
mental effect on the ovaries is determined by the total and 
local radiotherapy dose in an age-dependent manner. The 
use of platinum as a radio-sensitizer in radiochemotherapy 
causes a potentiation of gonadotoxic effect. A radiother-
apy dose of 14.3 Gy will cause complete ovarian insuf-
ficiency (sterilization) in 97.5% of women at age 30 [46] 
(Table 2). Craniolateral transposition of the ovaries should 
be considered.
Radiotherapy to the uterus in cervical cancer involves a 
total dose of 40–50 Gy and a boost of 9 Gy as a combination 
of percutaneous radiotherapy and brachytherapy. A uterine 
dose of more than 45 Gy is not compatible with future preg-
nancies [47] (Table 3).
Risk of ovarian metastasis
Ovarian metastases in early stages of cervical carcinoma 
without risk factors are infrequent, however, in adenocar-
cinoma in young women, the risk is significantly increased 
compared to squamous cell carcinoma (8.2 vs. 0.4%, respec-
tively) [48–50].
Fertility preservation measures
In cervical carcinoma in situ, cone-biopsy or LLETZ do not 
impair fertility, when the surgical technique aims at pre-
serving cervical function during future pregnancy [51]. In 
microinvasive carcinoma FIGO IA1 with one risk factor and 
in FIGO IA2 without risk factors, cone-biopsy is eligible for 
fertility preservation, if a complete resection of the tumour 
Table 3  Clinical effects of 
radiotherapy to the uterus. 
Modified from [47]
Gy gray, TBI total body irradiation
Radiotherapy during childhood has a more harmful effect on the uterus than during adulthood
Radiotherapy to an adult uterus during total body irradiation (TBI) with 12 Gy is associated with an 
increased risk of miscarriage, premature birth and low birth weight
After radiotherapy to the uterus with a dose > 25 Gy during childhood, pregnancy is not advisable
After radiotherapy to the uterus with a dose > 45 Gy during adulthood, pregnancy is not advisable
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is achieved (R0). Oncological results are comparable to hys-
terectomy [52, 53].
In FIGO IA2 plus one risk factor and in FIGO IA1 plus 
two risk factors, staging which confirms negative lymph 
node status is required to allow fertility sparing radical tra-
chelectomy including cerclage [54, 55]. Long-term outcome 
appears comparable to radical hysterectomy [56, 57]. In 
FIGO IB1 < 2 cm and no risk factors, radical trachelectomy 
is also possible in selected cases.
For FIGO IB1 ≥ 2 cm, radical hysterectomy with bilateral 
salpingectomy is indicated and preservation of the uterus is 
not possible. While preservation of the ovaries is possible 
in early squamous epithelial carcinoma, in adenocarcinoma, 
which carries a higher risk for ovarian metastases, this may 
be individually decided for FIGO < IB2 [58].
When cone-biopsy or trachelectomy are performed for 
fertility preservation in cervical cancer instead of radical 
hysterectomy, an increased risk of relapse must be discussed 
with the patient. In addition, an increased risk of miscar-
riage and premature birth must be considered [57, 59–62]. 
Downstaging by neo-adjuvant chemotherapy in advanced 
cervical cancer for uterus preservation has been described, 
but is currently considered experimental [63].
Craniolateral ovarian transposition can be performed 
before radiochemotherapy in selected cases. However, the 
surgical procedure itself can be associated with a reduction 
in the ovarian reserve [64].
Currently, it is under discussion whether GnRH agonists 
reduce the gonadotoxicity of chemotherapy. Ovarian tissue 
cryopreservation can be discussed, but the risk of ovarian 
metastases must be considered in adenocarcinoma. If legal 
in the respective country, surrogacy after oocyte cryopreser-
vation could be an option in cases, where preservation of the 
uterus is not possible.
Summarized recommendations
• Fertility sparing surgery such as cone-biopsy or LLETZ 
is recommended in microinvasive cervical carcinoma 
FIGO IA1 with one risk factor and in FIGO IA2 without 
risk factors and if R0 resection is achieved.
• In FIGO IA1 with two risk factors and in FIGO IA2 with 
one risk factor, fertility preserving surgery in the form of 
radical trachelectomy according to D’Argent is possible, 
when staging confirms N0.
• In FIGO IB1 < 2 cm, radical trachelectomy with preser-
vation of the ovaries is possible, the increased oncologi-
cal risk must be individually assessed.
• In FIGO IB ≥ 2 cm, uterus preservation is not possible.
• In cervical adenocarcinoma FIGO < IB2, the ovaries may 
be preserved in an individual decision.
• Craniolateral transposition of ovaries is an eligible pro-
cedure before radiotherapy.
• If the uterus cannot be preserved, ovarian stimulation 
and oocyte cryopreservation followed by surrogacy is an 
option, if legal in the respective country.
• Downstaging cervical cancer by neo-adjuvant chemother-
apy to preserve the uterus is controversially discussed.
Endometrial carcinoma and endometrial 
hyperplasia
Prognosis
The prognosis in complex endometrial hyperplasia without 
and with atypia is excellent after progestin therapy and his-
tological follow-up with hysteroscopy and curettage. In early 
endometrial carcinoma FIGO IA G1/G2, frequent in younger 
women < 45 years, standard therapy by hysterectomy with 
salpingo-oophorectomy is associated with a very good prog-
nosis and a 5-year survival rate of 94%.
Risks to fertility
Therapy with progestin is not gonadotoxic, but delays reali-
zation of pregnancy. In endometrial carcinoma, the standard 
surgical procedure of hysterectomy with salpingo-oopho-
rectomy is not compatible with fertility, but fertility sparing 
strategies exist for FIGO IA G1. Radiotherapy is indicated 
in higher stages of endometrial cancer not eligible for fertil-
ity preservation.
Risk of ovarian metastasis
The risk of ovarian metastasis in early endometrial carci-
noma appears to be low [65]. Synchronous ovarian cancer 
may be present, especially in women with Lynch syndrome 
[66].
Fertility preservation measures
In complex endometrial hyperplasia without atypia, cyclic 
progestin therapy is indicated (e.g., 10–20 mg MPA/day), 
followed by control hysteroscopy and curettage after 
3–6 months before pregnancy is achieved. Alternatively, 
pregnancy is realized first, followed by progestin therapy.
In complex endometrial hyperplasia with atypia, proges-
tin therapy with 100 mg MPA/day with hysteroscopic and 
histological follow-up after 3 and 9 months is indicated, fol-
lowed by the realization of pregnancy.
In well-differentiated type I endometrial carcinoma without 
infiltration of the myometrium FIGO IA G1, hysteroscopy and 
curettage for tumour removal is possible, followed by progestin 
therapy for 6–12 months (e.g., 250 mg MPA/day or a progestin 
containing intrauterine device). Hysteroscopic follow-up and 
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curettage are required every 3 months. After cessation of pro-
gestin, the realization of a pregnancy is possible in a limited 
time interval. After pregnancy, stage-adjusted completion of 
surgery by hysterectomy and salpingo-oophorectomy is indi-
cated, because of a high recurrence risk [67–70].
The preservation of the uterus and adnexa in endometrial 
carcinoma is associated with an increased oncological risk, 
because of inadequate staging. A risk of ovarian metastasis 
or synchronous primary ovarian carcinoma must be consid-
ered, probably being < 1% in early endometrial carcinoma in 
young women [71, 72]. However, the preservation of ovaries 
in low-grade endometrial carcinoma does not appear to impair 
recurrence-free intervals [73, 74].
IVF has been proposed to reduce the time to pregnancy 
before a completion of surgery [75, 76]. Hormonal stimula-
tion for oocyte cryopreservation appears possible, if stimulated 
estradiol levels are reduced with an aromatase-inhibitor or an 
anti-oestrogen and ovulation is induced by a GnRH agonist. 
Ovarian tissue cryopreservation appears possible in early 
endometrial carcinoma, because of a low risk of metastases.
Summarized recommendations
• In endometrial hyperplasia without atypia, cyclic proges-
tin therapy is indicated (e.g., 10–20 mg MPA/day), with 
follow-up hysteroscopy and curettage after 3–6 months 
before a pregnancy is achieved.
• In endometrial hyperplasia with atypia, MPA 100 mg/day 
or a progestin-releasing IUD is indicated, with follow-up 
hysteroscopy and curettage after 3 and after 9 months, 
before pregnancy can be achieved.
• In individual cases of progesterone receptor-positive 
endometrial carcinoma FIGO IA G1, tumour removal 
by hysteroscopy and curettage is possible for fertility 
preservation, followed by progestin therapy with 250 mg 
MPA for 6–12 months with follow-up in three-monthly 
intervals. The realization of a pregnancy is then possible 
within a limited time frame. After pregnancy or in case 
of relapse, completion of surgery is indicated.
• Fertility preservation is not possible in progesterone 
receptor-negative endometrial carcinoma FIGO IA G1, 
or in tumours with higher stages or higher grading. In 
these cases, hysterectomy with bilateral salpingo-oopho-
rectomy is indicated.
Rheumatic and autoimmune disorders
Prognosis
Rheumatic and autoimmune disorders cannot be cured; how-
ever, life expectancy can be significantly improved when 
treated adequately.
Risks to fertility
Ovarian reserve is impaired by cyclophosphamide (CYC), 
which is used for immune suppression over a limited time 
interval in highly active disease stages (orally or as an 
intravenous pulse therapy). While a single treatment cycle 
appears to have limited gonadotoxicity, repeated cycles are 
needed to control the disease and may be necessary again 
throughout the patient’s life, increasing the cumulative 
CYC-dose. CYC significantly increases the risk of prema-
ture ovarian insufficiency (POI) in patients with autoimmune 
diseases, ranging from 12 to 54% in the literature, depend-
ing on age and cumulative CYC-dose [77, 78]. In addition, 
ovarian reserve can be reduced by the autoimmune disease 
per se [79–81]. Consultation about fertility preservation in 
autoimmune diseases, therefore, is recommended before 
CYC-therapy [82].
Fertility preservation measures
The following recommendations are mainly based on evi-
dence available for systemic lupus erythematosus (SLE), 
because limited data exist for other autoimmune diseases.
Female sex steroids are assumed to contribute to the 
pathogenesis of SLE, which could account for the observed 
exacerbation of the disease during ovarian stimulation for 
fertility preservation. In contrast, positive effects on the 
disorder associated with GnRH agonists suppressing ovar-
ian function have also been observed [83]. In this context, 
the exacerbation risk of rheumatic disorders during GnRH 
agonist therapy is low. While their efficacy in fertility pres-
ervation for other disorders appears to vary [84], a protec-
tive effect of GnRH agonists specifically in autoimmune 
disorders has been observed [85–88]. A recent consensus 
recommends GnRH agonists for young women with SLE 
who are receiving alkylating agents [82].
Ovarian stimulation is associated with a significant exac-
erbation risk in SLE, which is probably little less present in 
primary antiphospholipid syndrome (APS) [89]. The risk 
of venous thromboembolism (VTE) is increased in auto-
immune disorders, being the highest in active stages of 
APS and SLE. When lupus anticoagulant is present, VTE 
risk is increased sixfold [90]. Data on VTE risk associated 
with ovarian hormonal stimulation in autoimmune disease 
is limited. No VTE was observed in a study on 68 stimu-
lated cycles of 19 patients with SLE and APS who received 
antithrombotic prophylaxis [89]. In active stages of auto-
immune diseases, hormonal stimulation for fertility pres-
ervation may be considered in individual cases; sufficient 
VTE-prophylaxis is required [82]. However, especially in 
connective tissue diseases, hormonal stimulation may not 
be indicated because of the exacerbation risk.
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Cryopreservation of ovarian tissue is an eligible option 
in autoimmune disorders. A disease-related reduction of the 
ovarian reserve should be evaluated in advance.
Summarized recommendations
• Fertility preservation should be recommended in young 
women with autoimmune disorders, when CYC-therapy 
is indicated.
• GnRH agonists are an eligible option for fertility preser-
vation in autoimmune diseases.
• Ovarian stimulation and cryopreservation of oocytes can 
be applied in individual cases, if risk of exacerbation is 
low and sufficient time is available. Effective thrombosis 
prophylaxis is required.
• Cryopreservation of ovarian tissue is an option, if ovarian 
reserve is sufficient.
Other malignant diseases
Ewing sarcoma
Prognosis
The prognosis in Ewing sarcoma is categorized into risk 
classes according to the 5-year survival rate (in brackets):
• Standard risk (70–75%): localized tumour, good response 
to neo-adjuvant chemotherapy.
• High risk (50%): localized tumour, volume > 200 ml, 
reduced response to neo-adjuvant chemotherapy, pul-
monary metastases.
• Very high risk (20–40%): all other.
Risks to fertility
Chemotherapy-related premature ovarian insufficiency (POI) 
in Ewing sarcoma occurs in ≥ 50% of patients. A signifi-
cantly higher risk of infertility is expected in case of pelvic 
radiotherapy or haematopoietic stem cell transplantation 
[91].
Risk of ovarian metastasis
Ovarian metastases were observed in single cases [14, 50, 
92–94], but were not confirmed in all the studies [95].
Fertility preservation measures
GnRH agonists and, if the time interval before oncologi-
cal therapy is sufficient, ovarian stimulation with oocyte 
cryopreservation can be considered. Ovarian tissue cryo-
preservation is possible. A risk of ovarian metastasis must 
be discussed. Ovarian transposition is possible, if pelvic 
radiotherapy is performed [96].
Osteosarcoma
Prognosis
The prognosis of osteosarcoma depends on tumour stage 
with a 5-year survival rate of 20–80%.
Risks to fertility
The risk of premature ovarian insufficiency (POI) was 
reported to affect 6 of 90 women, after chemotherapy (6.6%) 
[97].
Risk of ovarian metastasis
Ovarian metastases are possible, but were not detected in 
small studies [14, 92].
Fertility preservation measures
Comparable to Ewing sarcoma, GnRH agonists and, if the 
time interval before oncological therapy is sufficient, ovarian 
stimulation with oocyte cryopreservation can be considered. 
Ovarian tissue cryopreservation is possible, if the risk of 
ovarian metastasis is discussed. Ovarian transposition is pos-
sible, if pelvic radiotherapy is performed [96].
Colorectal carcinoma
Prognosis
The 5-year survival rate in tumour stages pT1–3 after 
R0-resection in colorectal carcinoma is 90, 80, 60% and in 
rectal carcinoma 90, 70, 40%, respectively.
Risks to fertility
The chemotherapy-induced risk of premature ovarian 
insufficiency (POI) is low to moderate, but high if radio-
chemotherapy is performed [98–100]. A radiotherapy dose 
of 45–50 Gy causes POI in > 90% of patients with rectal 
carcinoma.
Risk of ovarian metastasis
The risk of ovarian metastasis seems to be low in tumour 
stages pT1–3 [14, 50].
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Fertility preservation measures
If chemotherapy is indicated, GnRH agonists, ovarian 
stimulation for cryopreservation of oocytes, and ovarian 
tissue cryopreservation are possible options for fertility 
preservation. Ovarian transposition should be considered, 
if radiotherapy is performed. Gestational surrogacy after 
cryopreservation of oocytes or ovarian tissue may be an 
option, if legal in the respective country.
Non‑Hodgkin lymphoma (NHL)
Prognosis
The prognosis in NHL varies greatly and depends on the 
respective entity of the heterogeneous disease.
Risks to fertility
The risk for the ovarian reserve in NHL is determined by 
chemotherapy and radiotherapy. It can be high with a POI 
rate of 40–60% in women of age > 35 years for CHOP and 
VA-CHOP-B [101, 102] (Table 1).
Risk of ovarian metastasis
The risk of ovarian metastasis is high in high-grade NHL 
and Burkitt’s lymphoma [103]. Other types of NHL exhibit 
a lower, but still clinically relevant risk [14, 32].
Fertility preservation measures
GnRH agonists are an option for fertility preservation. 
Ovarian transposition can be considered, if pelvic radio-
therapy is performed. Ovarian stimulation for cryopreser-
vation of oocytes, and ovarian tissue cryopreservation 
are not recommended, because of the risk of ovarian 
metastasis.
Acute lymphoblastic leukaemia (ALL)
Prognosis
The 5-year survival rate in children is 80–90%, but much 
lower in adults with a range of 20–45% depending on the 
age group [104, 105].
Risks to fertility
A moderate to high POI risk is conveyed by chemotherapy 
in ALL; the risk is very high in autologous or allogenic 
stem cell transplantation (Table 1).
Risk of ovarian metastasis
ALL conveys a high risk for ovarian involvement with 
leukaemic cells [50, 92, 106].
Fertility preservation measures
GnRH agonists are an option for fertility preservation. 
GnRH agonist-induced amenorrhoea prevents menstrual 
bleeding during oncological therapy. Ovarian stimulation 
with cryopreservation of oocytes is often not possible due 
to the limited time available. Ovarian cryopreservation is 
experimental because of the high risk of ovarian malignant 
cells. In vitro growth (IVG) or xenotransplantation may 
become future strategies.
Acute myeloid leukaemia (AML)
Prognosis
The 5-year overall survival rate is 24–80% in adults 
depending on the r isk group, and 60% in chil-
dren < 15 years [104].
Risks to fertility
The risk of POI conveyed by chemotherapy is moderate to 
high; in autologous or allogenic stem cell transplantation, it 
is very high [107] (Table 1).
Risk of ovarian metastasis
The risk of malignant cells in the ovaries is high [50, 92].
Fertility preservation measures
Comparable to ALL, GnRH agonists are an option for 
fertility preservation in AML and GnRH agonist-induced 
amenorrhoea prevents menstrual bleeding during oncologi-
cal therapy. Ovarian stimulation with cryopreservation of 
oocytes is often not possible due to the limited time availa-
ble. Ovarian tissue cryopreservation is experimental because 
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of the high risk of ovarian malignant cells. In vitro growth 
(IVG) or xenotransplantation may become future strategies.
Effects of radiotherapy
Gonadal function
The effects of radiotherapy on the ovaries are difficult to esti-
mate because of individual variation. Table 2 gives an over-
view of some effects and the respective radiotherapy dose.
Uterine function
After total body irradiation (TBI) with a median of 10 Gy, 
a birth weight of < 2500 g was found in approximately 30% 
of children, compared to 10% of controls without radio-
therapy [108]. After direct pelvic radiotherapy, only scarce 
data are available [109–111]. In a systematic analysis, it was 
observed that radiotherapy during childhood appears to have 
stronger detrimental effects on the uterus than in adulthood. 
Radiotherapy to the uterus in TBI of 12 Gy was associated 
with a higher risk of miscarriage, premature birth and low 
birth weight. After a radiotherapy dose of > 25 Gy dur-
ing childhood, a pregnancy is not advisable; in adulthood, 
the respective upper limit is 45 Gy [47]. Table 3 shows the 
effects of different radiotherapy doses on the uterus.
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